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Abstract 
Background 
Screening and Brief Interventions (SBIs) for heavy drinking are an effective and cost-effective 
approach to reducing alcohol-related harm, yet delivery rates remain low. This study uses trial data 
to estimate the cost effectiveness of alternative strategies to increase SBI delivery. 
Methods 
Data from a large cluster-randomised trial were combined with the Sheffield Alcohol Policy Model, a 
policy appraisal tool, to estimate the cost effectiveness of eight strategies to increase SBI delivery in 
primary care in England, Poland and the Netherlands: care as usual (control), training and support 
(TS), financial reimbursement (FR), referral of patients to an online intervention (eBI) and all 
combinations of TS, FR and eBI. Cost-effectiveness was assessed from a healthcare perspective by 
comparing health benefits (measured in Quality-Adjusted Life Years (QALYs)) with total 
implementation costs and downstream healthcare savings for each strategy over a 30-year horizon 
and calculating Incremental Cost-Effectiveness Ratios (ICERs). 
Results 
All trialled strategies were cost-effective compared to control. TS combined with FR was the most 
cost-effective approach in England (more effective and less costly than control) and Poland (ICER 
 ? ? ? ? ? ?ǀƐ ?ŶĞǆƚďĞƐƚƐƚƌĂƚĞŐǇ ? ?dŚŝƐĐŽŵďŝŶĂƚŝŽŶŝƐŶŽƚĐŽƐƚ-effective in the Netherlands, where TS 
alone is the most cost-ĞĨĨĞĐƚŝǀĞĂƉƉƌŽĂĐŚ ?/Z ? ? ? ? ? ?ǀƐ ?ŶĞǆƚďĞƐƚƐƚƌĂƚĞŐǇ ? ? 
Conclusions 
Structured training and support, financial incentives and access to online interventions are all 
estimated to be cost-effective methods of improving delivery of alcohol brief interventions. TS and 
FR together may be the most cost-effective approach, however this is sensitive to country 
characteristics and alternative BI effect assumptions. 
Trial registration 
ClinicalTrials.gov trial identifier: NCT01501552 
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Introduction 
The harmful use of alcohol is one of the most important risk factors for disease, disability and death 
worldwide, with 4.2% of the global burden of disease and injury in 2016 estimated to be attributable 
to alcohol consumption (1). Besides these health consequences, alcohol-related harm is associated 
with significant negative economic and other impacts on society (2) and, as a result, there is an 
increasing awareness of negative effects of alcohol in public health policy (3). 
Screening and Brief Interventions (SBI), delivered in primary care, have been shown to be an effective 
(4,5) and cost-effective, or even cost-saving (6), policy option for the reduction of alcohol-related 
harm, although there are significant variations in the potential impacts of SBI programmes between 
countries (7). In spite of this promise, delivery rates by primary health care practitioners have been 
found to be consistently low, with only around 1 in 20 eligible patients being screened (8). These rates 
compare extremely unfavourably to those for Brief Interventions for smoking, which are supported by 
a similarly robust evidence base, with a recent UK study finding an eightfold difference in Brief 
Intervention delivery rates for smoking and drinking (9). 
A wide range of approaches, including the provision of training, support and financial reimbursement, 
have been identified as potentially effective levers to improve the uptake of SBIs among primary care 
practitioners (10). Online Brief Interventions (often referred to as eBI) have also emerged as a 
potentially effective alternative to face-to-face interventions which may reduce the burden on 
ŚĞĂůƚŚĐĂƌĞƉƌŽǀŝĚĞƌƐ ?ƚŝŵĞ(11). The recent Optimising Delivery of Health care Interventions (ODHIN) 
trial tested the effects of several of these strategies on SBI delivery rates and demonstrated that 
training and support and financial reimbursement are effective, particularly in combination, at 
increasing uptake in primary care (12). These strategies, however, have costs attached to them and it 
is unclear whether these approaches are cost-effective and if this varies between countries. Previous 
cost-effectiveness studies in this area have focussed only on online interventions in settings outside 
primary care (e.g. (13 ?15)). 
This study aims to address this gap by using the Sheffield Alcohol Policy Model, a widely-used alcohol 
policy appraisal tool which has previously been applied to assess the potential cost-effectiveness of 
SBIs across Europe (7,16,17),  to evaluate the long-term cost-effectiveness in England, the 
Netherlands and Poland of training and support, financial incentives and referral to online 
interventions at improving SBI delivery and the resulting effects on population health outcomes. The 
findings will enable policy makers to understand the potential costs and benefits of engaging in such 
programmes and make more informed health policy decisions when allocating potentially scarce 
resources. 
  
Methods 
ODHIN Trial design 
The ODHIN trial took place in 120 primary health care units (PHCUs) equally distributed across five 
countries (England, Netherlands, Poland, Catalonia and Sweden). The trial examined the impact of 
three alternative strategies for improving the uptake of Screening and Brief Intervention (SBI) 
delivery in primary care:  
x Training and Support (TS) in which providers were offered two 1-2 hour face-to-face 
educational training sessions on SBI and follow-up telephone support 
x Financial Reimbursement (FR) in which providers were offered financial incentives for 
screening and intervention delivery 
x Referral to an Online Brief Intervention (eBI) in which providers were able to refer patients 
identified as risky drinkers to an online-based intervention.  
Practices were randomised to either control or any combination of the three strategies (e.g. TS alone 
or FR together with eBI) to give eight arms in total. See the trial protocol or outcomes report for 
further details on the trial design (12,18). 
Trial outcomes 
The trial collected data on three key performance measures of SBI delivery: 
1) The screening proportion  ? the proportion of eligible patients who were screened for heavy 
drinking using the AUDIT-C screening tool1 
2) The screen positive proportion  ? the proportion of screened patients who were identified as 
heavy drinkers by the screening test2. 
                                                          
1 A small number of patients in Catalonia were screened using an alternative screening tool, ALRIS, although 
practitioners were encouraged to use AUDIT-C wherever possible. 
2 Screen positives were defined in Catalonia and ŶŐůĂŶĚĂƐŵĞŶĂŶĚǁŽŵĞŶǁŚŽƐĐŽƌĞĚA? ?ŽŶh/d-C and in 
WŽůĂŶĚ ?EĞƚŚĞƌůĂŶĚƐĂŶĚ^ǁĞĚĞŶĂƐŵĞŶǁŚŽƐĐŽƌĞĚA䠃?ĂŶĚǁŽŵĞŶǁŚŽƐĐŽƌĞĚA䠃?ŽŶh/d-C 
3) The Brief Intervention proportion  ? the proportion of patients who screened positive on 
AUDIT-C who subsequently received a Brief Intervention 
 
Trial data was collected at three time points  ? baseline (i.e. pre-intervention), during a 12-week 
implementation period at which time the strategies were being implemented, and during a 4-week 
follow-up period 6-months later (i.e. post-intervention). The baseline values of each measure were 
derived for each country, and the effect of each strategy on each measure during the 
implementation period and at follow-up, as presented in Table 1. See Appendix A for further details 
of this analysis. Whilst the trial took place across five countries, versions of the Sheffield Alcohol 
Policy Model, used to estimate the long-term costs and effects of the trialled strategies, were only 
available for three of these countries: England, Netherlands and Poland. Full details of these models 
have previously been published (16,19). The analysis presented here therefore focusses on these 
three countries.  
TABLE 1 ABOUT HERE 
For each country data was also collected on the costs associated with implementing each strategy, as 
summarised in Appendix B. Costs specific to organising the trial itself were excluded (e.g. the cost of 
ƉƌŝŶƚŝŶŐƚŚĞƚĂůůǇƐŚĞĞƚƐƵƐĞĚƚŽƌĞĐŽƌĚƉƌĂĐƚŝƚŝŽŶĞƌƐ ?^/ĂĐƚŝǀŝƚǇ ? ?Finally, full details of the structure 
of the financial incentives offered to providers in FR arms of the trial were collected (as each country 
set their own incentive structure using the budget allocated within the trial). This data was used to 
estimate, for each strategy in each country, the long-term costs of implementation in primary care at 
a national level using data on the total number of practitioners, practices and patients in each country. 
See Appendix B for full details.  
Modelling health outcomes 
The SBI delivery outcomes collected in the trial were converted into long-term health outcomes, in 
terms of Quality-Adjusted Life Years (QALYs) and healthcare costs associated with the treatment of 
alcohol-related health conditions, using the Sheffield Alcohol Policy Model (SAPM). SAPM is a causal 
epidemiological model which has previously been used to appraise pricing and SBI policies in 
England, the Netherlands and Poland (16,19,20) and whose findings have informed the development 
of primary care guidelines for the treatment of alcohol problems in the UK and the Netherlands 
(21,22). The model synthesises published evidence and country-specific data on current alcohol 
consumption, mortality and hospitalisation rates for 48 different alcohol-related health conditions, 
primary care usage, healthcare service utilisation costs and health-related quality of life data in order 
to estimate the proportion of the total adult population (18+ years) who would receive a brief 
intervention over a 10-year time horizon. The model then estimates the resulting changes in alcohol 
consumption and subsequent changes in mortality, hospitalisations and healthcare costs. Health 
outcomes are reported at a 30-year time horizon in order to account for the time lags which exist 
between changes in alcohol consumption and changes in risk of alcohol-related harm (23). Full 
methodological details of SAPM have previously been published elsewhere (24,25). 
A key challenge in estimating the impact of the trial strategies on SBI delivery over a 10-year period is 
that ?ǁŚŝůƐƚdƌĂŝŶŝŶŐ ?^ƵƉƉŽƌƚĂŶĚĞ/ƐƚƌĂƚĞŐŝĞƐĂƌĞĞƐƐĞŶƚŝĂůůǇ ‘ŽŶĞ-ŽĨĨ ?ƉŽůŝĐŝĞƐ ?ŝŶƚŚĞƐĞŶƐĞƚŚĂƚ
practitioners are trained or introduced to the eBI tool at the outset and not subsequently re-trained, 
Financial Reimbursement requires continuous investment. The follow-up measures are therefore not 
directly comparable across all strategies as practices allocated to TS and eBI strategies were essentially 
still under implementation conditions (e.g. practitioners could still refer patients to the eBI tool), whilst 
those allocated to FR strategies were not under implementation conditions, as no further payments 
were made after the 12-week implementation period. In order to overcome this issue, two separate 
long-term analyses were conducted. First, Ă ‘trial only ? analysis models exactly what was implemented 
in the trial (i.e. FR withdrawn after 12 weeks) and assumes that the effects observed at follow-up 
would be sustained in the long term. Second, Ă  ‘ĨƵůů ŝŵƉůĞŵĞŶƚĂƚŝŽŶ ? analysis models FR payments 
continuing for the full 10 years and assumes, as observed in previous SBI studies (e.g. (26)), that the 
effect of these on provider behaviour is maintained in the long term.  As a sensitivity analysis within 
the full implementation analysis, we also examine the impact of assuming that training must be re-
delivered every five, or every two, years in order to achieve this persistence of effect. 
In order to incorporate the three SBI delivery measures recorded in the trial into SAPM, two 
modifications are required to the country-specific models. First, the probability that any individual 
who receives a screen, screens positive is estimated from their alcohol consumption and demographic 
characteristics using a logistic regression whose parameters are calibrated to ensure that the modelled 
screen positive proportion matches that estimated from the trial data  ?see Appendix C for full details. 
Second, the model was adapted to account for the fact that not all patients who screen positive 
actually receive an intervention in practice using data from the trial as reported in Table 1. Receipt of 
an intervention is assumed to lead to a 12.3% reduction in mean alcohol consumption in line with 
evidence from a Cochrane review on the effectiveness of BIs in primary care (4). This reduction is 
assumed to decay linearly back to age-adjusted pre-intervention consumption levels over the 
following 7 years as suggested by long-term follow up evidence from a previous trial (27). Due to the 
uncertainty in this persistence of effect, we test a more conservative assumption of 3 years in a 
sensitivity analysis. It is assumed that no individuals are screened more than once over the 10-year 
SBI implementation period. 
Health Economic analysis 
For each of the three countries (England, Netherlands and Poland), for each of the eight strategies 
(control, TS, FR, eBI, TS+FR, TS+eBI, FR+eBI, TS+FR+eBI), we conducted three primary analyses. 
Firstly, we model the number of BIs delivered and the associated implementation and delivery costs 
ŽǀĞƌƚŚĞ ?ŵŽŶƚŚƚƌŝĂůƉĞƌŝŽĚ ?dŚŝƐƉƌŽĚƵĐĞƐĂ ‘ǁŝƚŚŝŶ-ƚƌŝĂů ?ĞƐƚŝŵĂƚĞŽĨƚŚĞĐŽƐƚƉĞƌĂĚĚŝƚŝŽŶĂů/
delivered over control. Subsequently we present a full long-term cost-utility analysis for each of the 
two sceŶĂƌŝŽƐ ? ‘ƚƌŝĂůŽŶůǇ ?ĂŶĚ ‘ĨƵůůŝŵƉůĞŵĞŶƚĂƚŝŽŶ ? ?ĨƌŽŵƚŚĞƉĞƌƐƉ ĐƚŝǀĞŽĨƚŚĞŚĞĂůƚŚĐĂƌĞƐǇƐƚĞŵ ?
Total QALYs accrued in each scenario are estimated from SAPM alongside estimates of the 
healthcare costs associated with alcohol. These are combined with the estimated costs of 
implementing the eight strategies and the costs associated with actual SBI delivery for each country 
to estimate the net cost of each strategy over 30 years. Within each country and scenario, these net 
costs and QALY gains are compared to give Incremental Cost-Effectiveness Ratios (ICERs) for every 
strategy. These are compared to national cost-effectiveness thresholds to determine the most cost-
effective strategy for each country under each scenario. All costs are converted to 2016 Euros using 
OECD Purchasing Power Parities (28) and all costs and health benefits are discounted using locally-
appropriate discount rates for each country (see Appendix D for full details). 
  
Results 
Within-trial analysis 
Results from the within-trial analysis in Table 2 show that all strategies are estimated to increase the 
numbers of BIs delivered across the population in all countries. TS+FR is the most effective strategy 
at increasing BI delivery, although it has one of the highest marginal costs for each additional BI 
delivered across all three countries. In contrast, eBI appears to offer the cheapest way to achieve 
delivery of additional BIs, although it is among the least effective strategies overall.  
TABLE 2 ABOUT HERE 
Trial only cost-effectiveness analysis 
Results from the trial only analysis in Table 3 show that TS+FR is the strategy which produces the 
largest health benefits while remaining cost-effective across all three countries. The ICERS of  ? ? ? ? ?7, 
 ? ? ? ?53 ĂŶĚ ?8,319 in England, the Netherlands and Poland respectively compared to the next-best 
alternative ĂƌĞĂůůƐƵďƐƚĂŶƚŝĂůůǇůŽǁĞƌƚŚĂŶƚŚĞƌĞƐƉĞĐƚŝǀĞƚŚƌĞƐŚŽůĚƐŽĨ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?ĂŶĚ
 ? ? ? ? ? ? ?ďĞůŽǁǁŚŝĐŚŝŶƚĞƌǀĞŶƚŝŽŶƐĂƌĞŐĞŶĞƌĂůůǇĐŽŶƐŝĚĞƌĞ cost-effective. In both England and the 
Netherlands the FR strategy dominates control (i.e. it produces greater health benefits while costing 
less) ?ĂůƚŚŽƵŐŚƚŚĞƐĐĂůĞŽĨƐĂǀŝŶŐƐŝƐǀĞƌǇĚŝĨĨĞƌĞŶƚďĞƚǁĞĞŶƚŚĞƚǁŽĐŽƵŶƚƌŝĞƐ ? ? ?5 ?ŵĂŶĚ ? ?.8m 
respectively). Both TS and TS+FR strategies incur a net cost to the healthcare system in Poland, with 
ƚŚĞŵŽƐƚĞĨĨĞĐƚŝǀĞƐƚƌĂƚĞŐǇ ?d^A?&Z ?ĐŽƐƚŝŶŐ ? ? ? ?ŵŽǀĞƌ ? ?Ǉ ĂƌƐĐŽŵƉĂƌĞĚƚŽĐŽŶƚƌŽů ? Estimated 
health gains under TS+FR are also larger in England, at 15,400 QALYs over 30 years compared to 
2,400 in the Netherlands and 2,600 in Poland. Full results for all strategies can be found in Appendix 
E. 
TABLE 3 ABOUT HERE 
 
 
Full implementation analysis 
Assuming that the costs and impacts of FR are maintained at implementation levels across the 
modelled 10-year implementation period leads to broadly similar results, shown in Table 4. TS+FR is 
still the optimal strategy in England and Poland, but the incremental analysis shows that it is no 
longer cost-effective in the Netherlands compared to TS alone  ?/Z ? ? ? ? ? ? ? ?. As for the within-trial 
analysis, the optimal strategies are estimated to be cost saving in England and the Netherlands, but 
not Poland, and the health gains in England are significantly larger than in the other countries. Full 
results for all strategies can be found in Appendix F. 
TABLE 4 ABOUT HERE 
Sensitivity analyses 
In order to investigate the uncertainty in our assumptions of continued effectiveness for strategies 
other than FR in the longer-term in the full implementation analysis, we tested the assumption that 
training had to be re-delivered every 5 or every 2 years in order to achieve this persistence of effect 
(at the same cost as the original training, before discounting). Full results for these alternative 
assumptions can be found in Appendix G.  
These alternative assumptions lead to significant increases in the costs associated with 
implementing all strategies involving Training & Support. For example, the cost over 10 years of 
ĚĞůŝǀĞƌŝŶŐd^ŝŶƚŚĞEĞƚŚĞƌůĂŶĚƐŝŶĐƌĞĂƐĞĚĨƌŽŵ ? ? ? ?ŵƚŽ  ? ? ? ? ?ŵǁŝƚŚƌĞƚƌĂŝŶŝŶŐĞǀĞƌǇ ?ǇĞĂƌƐĂŶĚ
 ? ? ? ? ?ŵǁŝƚŚƌĞƚƌĂŝŶŝŶŐĞǀĞƌǇ ?ǇĞĂƌƐ ?,ŽǁĞǀĞƌ ?ƚŚĞƐĞŝŶĐƌĞĂƐĞĚĐŽƐƚƐŵĂĚĞůŝƚƚůĞĚŝĨĨĞƌĞŶĐĞƚŽƚŚĞ
overall cost-effectiveness results and the overall conclusions of the analysis. The only significant 
change is that TS ceases to be cost-effective in the Netherlands if re-training is required every 2 
years, with eBI referral becoming the most cost-effective option under this scenario. 
Finally, we tested the impact on the trial only analysis of assuming a shorter persistence of effect of 
BI receipt on alcohol consumption. Full results for this can be found in Appendix H. As may be 
expected the overall cost-effectiveness is reduced for all strategies, however TS+FR remains the 
most cost-effective option for both England and the Netherlands, with ICERS of  ? ? ? ? ? ? ?ĂŶĚ ? ? ? ? ? ? ?
respectively. In contrast, this alternative assumption means that TS+FR is no longer estimated to be 
cost-effective in Poland, with TS alone offering the most cost-effective strategy with an ICER of 
 ? ? ? ? ? ? 
  
Discussion 
The findings of this study highlight that current SBI delivery rates in primary care are extremely low, 
while demonstrating that several cost-effective strategies exist to increase these rates. This analysis, 
which presents the first available estimates of the cost-effectiveness of strategies to increase these 
proportions, consistently shows that Training and Support or Training and Support in combination 
with Financial Reimbursement are effective and cost-effective strategies for increasing these 
delivery proportions. Modelling using only the trial data suggests that TS+FR is the most cost-
effective strategy in all countries, whilst assuming that increased screening proportions in practices 
receiving FR would be maintained if incentives continued to be paid makes TS+FR the optimal 
strategy in two of the three modelled countries, with TS alone the best option in the Netherlands. 
Sensitivity analyses show that these results are generally robust to more pessimistic assumptions of 
long-term effectiveness, although TS+FR may not to be cost-effective in Poland if the duration of 
effect of BIs is shorter than we have assumed in our base case. Whilst eBI alone is the least costly 
way of increasing BI delivery, and is estimated to be cost-effective versus control, as suggested by 
studies in other settings (13,15), this analysis shows that it is dominated by other strategies (i.e. it is 
less effective and costs more).  
There are a number of limitations to the methods used in this study, including those limitations 
inherent to SAPM which have been widely discussed previously (16,17,19,24), for example we do not 
model individuals who do not engage with primary care services, or explicitly model individual 
trajectories of alcohol consumption across the life course. There are also a number of assumptions 
relating to the trial data that should be considered alongside the results of this analysis. These include 
assumptions around the ongoing effect on provider behaviour of the eight strategies after the 6-
month follow-up in the trial. We have examined some of these assumptions in sensitivity analyses and 
it should be noted that other more pessimistic assumptions of long-term effects would lead to 
ŝŵƉůĞŵĞŶƚĂƚŝŽŶ ůĞǀĞůƐ ƐŽŵĞǁŚĞƌĞ ďĞƚǁĞĞŶ ƚŚĞ  ‘ƚƌŝĂů-only ? ĂŶĚ  ‘ĨƵůů ŝŵƉůĞŵĞŶƚĂƚŝŽŶ ? ĂŶĂůǇƐĞƐ
presented here. As both of these produce similar results, it is unlikely that reduced long-term effects 
would alter our conclusions. A further consideration is that the trial did not collect data on the 
demographics (or alcohol consumption) of those patients who consulted with, but were not screened 
by, participating practitioners. It is therefore difficult to determine whether the increased proportion 
of patients screening positive were a consequence of practitioners screening patients from different 
population groups which have a higher prevalence of risky drinking behaviour, or practitioners 
screening the same number of patients in each population group but with more successful 
identification of risky drinkers within each group. We have assumed the latter, but the impact of this 
assumption on the model results is unclear, as it will depend on the distribution of alcohol 
consumption and alcohol-related harms across the population in each country. We have used scenario 
analysis to explore key uncertainties in the model, however we have not been able to consider joint 
uncertainty across multiple input parameters, or attempt a full probabilistic analysis of uncertainty. 
Finally, as the focus of BI delivery in Europe is generally on early identification of potentially harmful 
drinking we have not explicitly modelled referral of patients identified as having some form of Alcohol 
Use Disorder to specialist treatment. As treatment itself is highly likely to be cost-saving (29,30) this 
exclusion means our estimates are likely to underestimate the true cost-effectiveness of each strategy. 
The finding that SBI programmes themselves are cost-effective has been widely replicated in many 
studies across many countries (e.g. (31,32)), however the costs and health benefits of such 
programmes between countries are likely to vary significantly (33). This is due to variation in 
underlying factors such as alcohol consumption, primary care usage, alcohol-related health and 
healthcare system costs as well as population (7). It is therefore perhaps unsurprising that the findings 
of this study suggest considerably variation in both costs and benefits of each strategy between 
countries, particularly since the trial results have shown there is additional variation between 
countries in terms of current screening. In spite of this heterogeneity, several clear patterns in the 
results that suggest some findings from this study may be generalizable to other countries with 
different healthcare systems and drinking cultures. Across all countries, TS is a relatively low-cost but 
effective policy option, while the addition of FR roughly doubles the health benefits at substantial 
additional cost. Across all countries, in spite of the relatively low cost of implementation and delivery 
of eBI programmes, these were consistently found to be less cost-effective than other strategies, 
perhaps related to a lack of familiarity or trust among practitioners of its efficacy (12,34). 
Whilst these results provide strong support for training programmes and the introduction of financial 
incentives, further research should address the questions of how to design training and support 
programmes and financial incentive structures to achieve maximum engagement with practitioners. 
One possibility, which could also potentially reduce training costs in the longer term, may be to embed 
an SBI component into routine training for primary care practitioners. Consideration for variation in 
provider response to different strategies, e.g. if training is more effective at encouraging practitioners 
who have not previously been delivering SBIs to start, or whether the effect is achieved through 
increasing delivery levels among practitioners who were already active, would also help in designing 
more effective, tailored approaches to increasing the delivery of Brief Interventions. Finally, relatively 
little is understood about the ways in which different subgroups of the population may respond to 
Brief Interventions and whether, as a result, greater effects on population health can be achieved 
through targeting interventions at certain patient groups. 
The findings of this study show that providing primary care providers with tailored training and 
support, financial incentives and the option to refer patients to an online intervention, either alone or 
in combination, are likely to be cost-effective options compared to providing no support or incentives 
to practitioners. Policy makers may, however, be mindful of the potential ethical issues associated 
with offering financial incentives to healthcare practitioners (35,36). Training and support and 
financial incentives together may offer the most cost-effective strategy for increasing delivery of 
Screening and Brief Interventions and so reducing alcohol-related harm and associated costs to 
society, although this finding is sensitive to both the characteristics of the country and also 
assumptions around the long-term effects of BIs.   
Conflict of Interest  
CA has received funding related to commissioned research from Systembolaget and Alko, the 
Swedish and Finnish government-owned alcohol retail monopolies. PA has received fees from AB 
InBev for public health comment on its goals to reduce the harmful use of alcohol, outside the 
submitted work. JL, ER, SP and AB have no interests to declare. 
Funding 
This work was supported by ƵƌŽƉĞĂŶhŶŝŽŶ ?Ɛ^ĞǀĞŶƚŚ&ƌĂŵĞǁŽƌŬWƌŽŐƌĂŵĨŽƌƌĞƐĞĂƌĐŚ ?
technological development and demonstration [grant agreement no. 259268]. The views expressed 
ŚĞƌĞƌĞĨůĞĐƚŽŶůǇƚŚĞĂƵƚŚŽƌƐ ?ĂŶĚƚŚĞƵƌŽƉĞĂŶhŶŝŽŶŝƐŶŽƚůŝĂďůĞĨŽƌĂŶǇƵƐĞƚŚĂƚŵĂǇďĞŵĂĚĞŽĨ
the information contained therein. 
Key Points 
x Current provision of Screening and Brief Advice in primary care is low across Europe 
x Training and Support, Financial Reimbursement and the opportunity to refer patients to an 
online tool, and all combinations of these strategies are likely to be cost-effective compared 
to current practice 
x Training and Support in combination with Financial Reimbursement is the most effective 
strategy at increasing SBI delivery, but also the most costly and as a result may not be cost-
effective in all countries 
x Referring patients to an online Brief Intervention is a low-cost way of increasing SBI delivery, 
although the scale of increase may be modest and other, more costly options are likely to be 
more cost-effective overall 
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Table 1 - Baseline Screening and Brief Intervention rates and the impact on these as 
estimated from the ODHIN trial 
  
Screening proportion 
Screen positive 
proportion 
Brief Intervention 
proportion 
Baseline   
 
  
Country 
England 4.6% 48.9% 85.9% 
Netherlands 5.3% 44.4% 70.4% 
Poland 2.0% 41.2% 95.8% 
Change between baseline and 
implementation 
     
Strategy 
Control -45.8% -7.1% 0.2% 
TS 59.8% -7.4% 21.2% 
FR 90.7% -12.5% 18.2% 
eBI 12.5% 3.8% 14.0% 
TS+FR 129.5% -15.8% 24.8% 
TS+eBI 28.0% -4.0% 17.8% 
FR+eBI 43.1% -6.3% 14.9% 
TS+FR+eBI 68.2% -20.6% 22.9% 
Change between baseline and 
follow-up 
     
Strategy 
Control -37.5% -8.4% -22.1% 
TS -9.5% -17.6% 7.5% 
FR -7.6% -16.8% 3.8% 
eBI -20.0% -1.4% 1.2% 
TS+FR 3.2% -27.8% 10.0% 
TS+eBI -8.3% -18.7% 3.1% 
FR+eBI -20.1% -13.4% 3.8% 
TS+FR+eBI 10.7% -35.3% 4.4% 
 
Table 2 ± Estimated additional Brief Interventions delivered and associated costs compared 
to control over trial period 
 
Additional BIs delivered Cost per additional BI 
England Netherlands Poland England Netherlands Poland 
TS 399,247 209,344 72,615  ? ? ?  ? ? ?  ? 18 
FR 433,430 302,798 103,166  ? ? ?  ? ? ?  ? ? ?
eBI 290,112 202,927 96,203  ? ? ?  ? ? ?  ? ? 
TS+FR 517,849 451,470 116,390  ? ? ?  ? ? ?  ? ? ?
TS+eBI 266,193 180,936 29,294  ? ? ?  ? ? ?  ? ? 
FR+eBI 315,354 206,759 12,411  ? ? ?  ? ? ?  ? ? ?
TS+FR+eBI 306,728 363,923 98,261  ? ? ?  ? ? ?  ? ? ?
  
Table 3 ± Trial-only analysis results for cost-effective strategies 
Country Strategy 
Net cost of 
programme 
 ? ?ŵ ?
Net 
QALY 
gain vs. 
no SBIs 
(,000s) 
Incremental 
ĐŽƐƚ ? ?ŵ ?
Incremental 
QALYs 
(,000s) ICER (per QALY) 
England 
Control -35.5 4.6   
FR -150.0 18.5 -114.5 13.8 Dominates 
TS+FR -145.1 20.0 4.8 1.5  ? ? ? ? ? ? 
Netherlands 
Control -4.0 1.0   
FR -7.8 2.3 -3.9 1.3 Dominates 
TS+FR -3.4 3.4 4.5 1.1  ? ? ? ? ? ? 
Poland 
Control 0.8 0.1   
TS 3.3 2.2 2.5 2.1  ? 1,168 
TS+FR 7.6 2.7 4.2 0.5  ? ? ? ? ? ? 
  
Table 4 ± Full implementation analysis results for cost-effective strategies 
Country Strategy 
Net cost of 
programme 
 ? ?ŵ ?
Net 
QALY 
gain vs. 
no SBIs 
(,000s) 
Incremental 
ĐŽƐƚ ? ?ŵ ?
Incremental 
QALYs 
(,000s) 
ICER (per 
QALY) 
England 
Control -35.4 4.6  
TS+FR -233.8 38.0 -198.4 33.4 Dominates 
Netherlands 
Control -4.0 1.0  
eBI -7.9 1.3 -3.9 0.4 Dominates 
TS -3.9 2.5 4.0 1.2  ? ? ? ? ? ? 
Poland 
Control 0.8 0.1  
TS 3.3 2.2 2.5 2.1  ? ? ? ? ? ? 
TS+FR 18.5 5.5 15.2 3.3  ? ? ? ? ? ? 
 
